Clinical Trials Browser

Interventional × Myasthenia Gravis × Cyclophosphamide × Clear all

NCT07526493 2026-04-13

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06193889 2026-04-06

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT07304154 2026-03-10

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Phase 1 Not yet recruiting

52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT04561557 2024-10-30

CARTinNS

Phase EARLY_PHASE1 Recruiting

36 enrolled

Plasma cell

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Autoimmune Diseases, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, POEMS Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT00424489 2018-08-31

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Phase 1 Terminated

9 enrolled 8 charts

Myasthenia Gravis